Evidence map›Paper›PMID 40406146›Full record

ArticleFrontiers in immunology2025

A conceptual exploration on the synergistic anti-tumor effects of high-order combination of OHSV2-DSTE

Shuang Dong, Xin Chen, Xiaoyu Li, Yang Wang, Qing Huang, Yuanxiang Li, Jing Jin, Xianmin Zhu, Yi Zhong, Qian Cai and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Shuang Dong *Department of Medical Oncology, Tongji Medical College, Hubei Cancer Hospital, Huazhong University of Science and Technology, Wuhan, China.
Xin Chen *College of Life Science and Technology, Huazhong Agricultural University, Wuhan, China.
Xiaoyu Li *Department of Medical Oncology, Tongji Medical College, Hubei Cancer Hospital, Huazhong University of Science and Technology, Wuhan, China.
Yang WangNational "111" Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei Provincial Cooperative Innovation Center of Industrial Fermentation, Hubei Key Laboratory of Industrial Microbiology, Hubei University of Technology, Wuhan, Hubei, China.
Qing HuangDepartment of Medical Oncology, Tongji Medical College, Hubei Cancer Hospital, Huazhong University of Science and Technology, Wuhan, China.
Yuanxiang LiDepartment of Medical Oncology, Tongji Medical College, Hubei Cancer Hospital, Huazhong University of Science and Technology, Wuhan, China.
Jing JinWuhan Binhui Biopharmaceutical Co., Ltd, Wuhan, China.
Xianmin ZhuDepartment of Medical Oncology, Tongji Medical College, Hubei Cancer Hospital, Huazhong University of Science and Technology, Wuhan, China.
Yi ZhongDepartment of Medical Oncology, Tongji Medical College, Hubei Cancer Hospital, Huazhong University of Science and Technology, Wuhan, China.
Qian CaiDepartment of Medical Oncology, Tongji Medical College, Hubei Cancer Hospital, Huazhong University of Science and Technology, Wuhan, China.
Chang XueDepartment of Medical Oncology, Tongji Medical College, Hubei Cancer Hospital, Huazhong University of Science and Technology, Wuhan, China.
Fang GuoDepartment of Pathology, Tongji Medical College, Hubei Cancer Hospital, Huazhong University of Science and Technology, Wuhan, China.
Le HuangCollege of Life Science and Technology, Huazhong Agricultural University, Wuhan, China.
Mingqian FengCollege of Life Science and Technology, Huazhong Agricultural University, Wuhan, China.
Binlei LiuNational "111" Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei Provincial Cooperative Innovation Center of Industrial Fermentation, Hubei Key Laboratory of Industrial Microbiology, Hubei University of Technology, Wuhan, Hubei, China.
Sheng HuDepartment of Medical Oncology, Tongji Medical College, Hubei Cancer Hospital, Huazhong University of Science and Technology, Wuhan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Although the treatment landscape for advanced hepatocellular carcinoma (HCC) has seen significant advancements in the past decade with the introduction of immune checkpoint inhibitors and antiangiogenic drugs, progress has fallen short of expectations. Recently, a novel engineered oncolytic virus (OHSV2) that secretes dual-specific T-cell engagers (DSTEs) targeting the fibroblast activation protein (FAP) was developed and combined with GPC3-targeting CAR-T cells and immunotoxins to exert a synergistic antitumor effect. Methods: OHSV2-DSTE Results: OHSV2-DSTE Conclusions: This high-order combination represents a novel multiple-wave immunotherapeutic approach for HCC. Despite being a conceptual exploration, this strategy has demonstrated promising therapeutic efficacy and acceptable safety profiles.

Indexed as

Carcinoma, HepatocellularImmunotherapy, AdoptiveImmunotoxinsLiver NeoplasmsOncolytic VirotherapyOncolytic VirusesReceptors, Chimeric AntigenT-LymphocytesAnimalsCD3 ComplexCell Line, TumorCombined Modality TherapyEndopeptidasesFibroblast Activation Protein AlphaGelatinasesHumansCD3 ComplexEndopeptidasesFibroblast Activation Protein AlphaGelatinasesImmunotoxinsMembrane ProteinsReceptors, Chimeric AntigenCAR-Tdual-specific T cell engagersFAPGPC3immunotherapyimmunotoxinsoncolytic virussynergistic effect

Identifiers

PMID40406146
PMCPMC12095149

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.